Real Life Experience of Combining Atezolizumab (Immunotherapy) and Bevacizumab (Antiangiogenic Agent) in Patients with Unresectable Hepatocellular Carcinoma in Bangladesh
Mamun Al Mahtab1*,Abdur Rahim2, Musarrat Mahtab3, Proshikha Saha4 and Sheikh Mohammad Fazle Akbar5
1,2Interventional Hepatology Division, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
3Department of Biochemistry and Biotechnology, North South University, Dhaka, Bangladesh
4Deapartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
5Department of Gastroenterology and Metabology, Ehime University, Japan
*Corresponding Author: Mamun Al Mahtab, Head, Interventional Hepatology Division, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
May 16, 2022; Published: May 19, 2022
Introduction: In a global, phase 3, multi-center,open label clinical trial combination of atezolizumab and bevacizumab has yielded encouraging results, including better survival benefit and safety in patients with unresectable hepatocellular carcinoma.
Methods: We conducted a real-life observational study in small number of Bangladeshi patents with unresectable HCC on the background of decompensated liver cirrhosis.
Results: We had 6 patients in our study and the patients took the drugs in diverse number of cycles. One of the patients who took six cycles of the drugs have been surviving for about 15 months. Atezolizumab and bevacizumab combination proved to be safe during 48 hours of follow up, however, long-term follow up had not been possible for all patients due to their unavailability after administration.
Conclusion: Atezolizumab and bevacizumab combination seem to have encouraging outcome with approved dosage and administration, however, clinical study with larger cohort should be accomplished in Bangladesh to properly assess its possible usage in Bangladeshi patients.
Keywords: Hepatocellular Carcinoma; Combination Immunotherapy; Atezolizumab; Bevacizumab
- Bray F., et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: A Cancer Journal for Clinicians 68 (2018): 394-424.
- Lau WY., et al. “Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma”. Annals of Surgery 233 (2001): 236-241.
- Zhu AX., et al. “Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open-label phase 2 trial”. Lancet Oncology 19 (2018): 940-952.
- El-Khoueiry AB., et al. “Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial”. Lancet 389 (2017): 2492-502.
- Finn RS., et al. “Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial”. Journal of Clinical Oncology 38 (2020): 193-202.
- Yau T., et al. “CheckMate 459: a randomized, multi-center phase 3 study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)”. Annals of Oncology 30 (2019): v874-v875.
- Morse MA., et al. “The role of angiogenesis in hepatocellular carcinoma”. Clinical Cancer Research 25 (2019): 912-920.
- Zhu AX., et al. “HCC and angiogenesis: possible targets and future directions”. Nature Reviews Clinical Oncology 8 (2011): 292-301.
- Motz GT., et al. “Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors”. Nature Medicine 20 (2014): 607-615.
- Roland CL., et al. “Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts”. Molecular Cancer Therapeutics 8 (2009): 1761-1771.
- Voron T., et al. “VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors”. Journal of Experimental Medicine 212 (2015): 139-148.
- Herbst RS., et al. “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients”. Nature 515 (2014): 563-567.
- Richard S Finn., et al. “Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma”. The New England Journal of Medicine20 (2020): 1895.
- Ferrara N., et al. “Bevacizumab (Avastin), a humanized anti- VEGF monoclonal antibody for cancer therapy”. Biochemical and Biophysical Research Communications 333 (2005): 328-335.
- Finn RS., et al. “Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model”. Liver International 29 (2009): 284-290.
- Marrero JA., et al. “Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases”. Hepatology 68 (2018): 723-750.